Peter Pockney

Peter Pockney

Auto-generated profile, based on publicly available information

Peter Pockney

School of Medicine and Public Health, The University of Newcastle, NSW, Australia; Discipline of Surgery, Medical School, The University of Western Australia, Perth, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2016 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
WSWolff Schmiegel
Wolff Schmiegel
Rodney ScottRodney Scott
Rodney Scott
SDSusan Dooley
Susan Dooley
WLWendy Lewis
Wendy Lewis
CMCliff J. Meldrum
Cliff J. Meldrum
SFStephen Fox
Stephen Fox
An accurate blood‐based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti‐EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether blood‐based RAS mutation testing is a viable alternative to standard‐of‐care RAS tumor testing. RAS testing was performed on plasma samples from newly diagnosed metastatic patients, or from recurrent mCRC patients using the highly sensitive digital PCR technology, BEAMing (beads, emulsions, amplification, and magnetics), and compared with DNA sequencing data of respective FFPE (formalin‐fixed paraffin‐embedded) tumor samples. Discordant tissue RAS results were re‐examined by BEAMing, if possible. The prevalence of RAS mutations detected in plasma (51%) vs. tumor (53%) was similar, in accord with the known prevalence of RAS mutations observed in mCRC patient populations. The positive agreement between plasma and tumor RAS results was 90.4% (47/52), the negative agreement was 93.5% (43/46), and the overall agreement (concordance) was 91.8% (90/98). The high concordance of plasma and tissue results demonstrates that blood‐based RAS mutation testing is a viable alternative to tissue‐based RAS testing.

1 October 2010 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
KRKate Reid
Kate Reid
PPPeter Pockney
Peter Pockney
BDBrian Draganic
Brian Draganic
SSStephen R. Smith
Stephen R. Smith
Surgical site infection following colorectal surgery is a frequent and costly problem. Barrier protection at the time of this form of surgery has been used with varying results. The aim of this randomized study was to examine the efficacy of barrier retractional wound protection in the prevention of surgical site infections in open, elective colorectal surgery. One hundred thirty consecutive patients undergoing open elective colorectal resectional surgery were randomly assigned to have either barrier retractional wound protection or standard wound retraction. Patients were then followed up for a minimum of 30 days postoperatively. The primary end point was surgical site infection as defined by the Centers for Disease Control and Prevention. The secondary end point was performance of the wound protector as assessed by operating surgeons. There was a significant reduction in the incidence of incisional surgical site infections when the wound protector was used: 3 of 64 (4.7%) vs 15 of 66 (22.7%); P = .004. Most surgical site infections were diagnosed after discharge from the hospital (78%), and there was no difference in the rates of reoperation, readmission, or formal wound drainage between the 2 groups. Surgeons found the wound protector to be helpful with retraction during surgery, with 88% (7/8) adopting it as part of their standard setup. In this study the use of barrier wound protection in elective open colorectal resectional surgery resulted in a clinically significant reduction in incisional surgical site infections. Barrier wound protection of this nature should be considered routine in this type of surgery.

23 June 2010 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
KRK. Reid
K. Reid
PPP. Pockney
P. Pockney
TPT. Pollitt
T. Pollitt
BDB. Draganic
B. Draganic
SSS. R. Smith
S. R. Smith

17 March 2017 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SSStephen R. Smith
Stephen R. Smith
PPPeter Pockney
Peter Pockney
RHRyan Holmes
Ryan Holmes
FDFiona Doig
Fiona Doig
JAJohn Attia
John Attia
BDBrian Draganic
Brian Draganic

1 April 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
JPJoel Petit
Joel Petit
GCGeorgia Carroll
Georgia Carroll
TGTiffany Gould
Tiffany Gould
PPPeter Pockney
Peter Pockney
Matthew DunMatthew Dun
Matthew Dun
RSRodney J. Scott
Rodney J. Scott

24 May 2022 in The Lancet Global Health
Verified
Journal Article
Open access
CSCatherine A Shaw
Catherine A Shaw
RPRiinu Pius
Riinu Pius
TDThomas M Drake
Thomas M Drake
LNLisa Norman
Lisa Norman
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
JLJean Wilguens Lartigue
Jean Wilguens Lartigue
Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. National Institute for Health and Care Research.